Return to previous page

IDD - Clinical Studies


IDD Clinical Studies
For printable copy
click here

To refer patients and/or discuss eligibility and other issues, please contact:


Clinical Studies Referral Office
Telephone: (210) 450-5798
Fax: (210) 616-5844
E-mail: onctrial@idd.org


New clinical studies are opening every day. If you did not find a clinical study for your cancer type and would like information about new studies that are opening please contact us by phone: (210) 450-5798 or email: onctrial@idd.org

Hematological Malignancies
Studies for cancer of the blood or bone marrow, such as leukemia or lymphoma
Organ Dysfunction
Studies that find the optimal dose/toxicity profile in patients who have impaired organ (liver or kidney) function that may alter the metabolism and elimination of a drug
Radiation Oncology
Studies that use high energy radiation to kill cancer cells and shrink tumors
Solid Tumors/
Non-Hematological
Studies for an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer)

New clinical studies are opening every day. If you did not find a clinical study for your category and would like information about new studies that are opening please contact us by phone: (210) 450-5798 or email: onctrial@idd.org

Phase I
This represents the first time a drug has been used in humans, and is used to evaluate how a drug should be given (by mouth, injected into the blood or injected into the muscle); how often; and what dose is safe. A Phase I study usually enrolls only a small number of patients, sometimes as few as a dozen
Phase II
A Phase II study continues to test the safety of the drug and begins to evaluate how well the new drug works, usually focusing on a particular type of cancer
Phase III
These studies test a new drug, a new combination of drugs, or a new surgical procedure in comparison to the current standard. A participant will usually be assigned to the standard group or the new group at random (called randomization). Phase III studies often enroll large numbers of people and may be conducted at many doctors' offices, clinics, and cancer centers nationwide
Phase 1b
Phase 1b studies are usually conducted in patients diagnosed with the disease, or condition for which the study drug is intended, who demonstrate some biomarker, surrogate, or possibly clinical outcome that could be considered for "proof of concept." Proof of concept in a Phase 1b study typically confirms the hypothesis that the current prediction of biomarker, or outcome benefit is compatible with the mechanism of action
Phase I/II

New clinical studies are opening every day. If you did not find a clinical study for your phase and would like information about new studies that are opening please contact us by phone: (210) 450-5798 or email: onctrial@idd.org